Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.34 |
| ▸ | DRD3 | P35462 | 5/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327045 | 0.90 | TAS2R14 (0.35) | HTR6DRD3TAS2R14HRH3AKR1C3 | |
| SCHEMBL21470487 | 0.86 | GHSR (0.36) | HTR6TAS2R14GPR119 | |
| SCHEMBL23326996 | 0.78 | TAS2R14 (0.36) | TAS2R14AKR1C3 | |
| SCHEMBL23327005 | 0.77 | TAS2R14 (0.35) | TAS2R14HRH3AKR1C3 | |
| SCHEMBL23326955 | 0.75 | TAS2R14 (0.35) | TAS2R14AKR1C3 | |
| SCHEMBL21470704 | 0.75 | GHSR (0.37) | TAS2R14 | |
| SCHEMBL23326956 | 0.75 | TAS2R14 (0.35) | TAS2R14AKR1C3 | |
| SCHEMBL23353650 | 0.75 | GHSR (0.36) | TAS2R14 | |
| SCHEMBL23353525 | 0.74 | GHSR (0.38) | HTR6TAS2R14 | |
| SCHEMBL21470771 | 0.74 | GHSR (0.37) | HTR6TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019200120-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | LYCERA CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |